Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Receivables - Net: 2021-2025

Historic Receivables - Net for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Sep 2025 value amounting to $33.0 million.

  • Rhythm Pharmaceuticals' Receivables - Net rose 71.11% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.0 million, marking a year-over-year increase of 71.11%. This contributed to the annual value of $18.5 million for FY2024, which is 24.52% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Receivables - Net stood at $33.0 million for Q3 2025, which was up 26.46% from $26.1 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Receivables - Net registered a high of $33.0 million during Q3 2025, and its lowest value of $862,000 during Q1 2022.
  • In the last 3 years, Rhythm Pharmaceuticals' Receivables - Net had a median value of $17.6 million in 2024 and averaged $18.0 million.
  • Data for Rhythm Pharmaceuticals' Receivables - Net shows a peak YoY skyrocketed of 841.65% (in 2023) over the last 5 years.
  • Over the past 5 years, Rhythm Pharmaceuticals' Receivables - Net (Quarterly) stood at $1.0 million in 2021, then spiked by 507.22% to $6.2 million in 2022, then skyrocketed by 138.87% to $14.9 million in 2023, then grew by 24.52% to $18.5 million in 2024, then spiked by 71.11% to $33.0 million in 2025.
  • Its last three reported values are $33.0 million in Q3 2025, $26.1 million for Q2 2025, and $17.8 million during Q1 2025.